Search   Advanced Search
LATEST NEWS
 
 
News
 Latest Headlines
 Quick Facts
 Breaking News
 Top Stories
 Feature Articles
 Politics
 US Policy
 General
 Commodities
 Canadian
 UK
 Indian
 Wallstreet Events
 Slide Shows
 US Economic News
 European Economic News
 Asian Economic News
 All Economic News
 FX Top Stories
 Currency Alerts
 Mkt Sensitive News
 Politics
 European Mkt Updates
 Asian Mkt Updates
 Treasury Mkt Updates
 Pop
 Rock
 Classic Rock
 Rap/Hip-Hop
 Country
 Alternative
 Oldies
 Movie Reviews
 DVD Releases
 Box Office
 Slide Shows
 Business News
Commentary/Analysis
 Daily Market Analysis
 US Market Updates
 US Commentary
 Asian Commentary
 European Commentary
 Canadian Commentary
 Indian Commentary
 Sector/Market Trends
Stock Alerts
 Stocks To Watch
 Long Term Stocks
 Before the Bell
 $5 and Under
 After the Bell
 Intraday Updates
 IPOs
 Hot Stocks
Earnings Calendars
 Upcoming Earnings
 Latest Earnings
 Pos Pre Announcements
 Neg Pre Announcements
Corporate Calendars
 Stock Splits
 Stock Buybacks
 Dividends
 Conference Calls
 FDA Calendar
 Board Meetings
 Mergers & Acquisitions
Ratings Changes
 Upgrades
 Downgrades
 Coverage Initiations
 Coverage Reiterated
 All Videos
 Market Commentary
 Top Stories
 Economic News
 Political News
 Foreign Markets
 Corporate News
 Entertainment News
 Top Stories
 Earnings
 Mergers & Acquisitions
 Market Commentary
 Economic News
 IPOs and New Issues
 Corporate News
 Forex News
 Interviews
 Private Equity
Economic Calendar
RTT DeskAlert
CES 2010 Coverage 

Follow Us
RTTNews on Twitter RTTNews on Facebook RTTNews on MySpace RTTNews on YouTube


Font Down Font Up
King Pharma Q3 Profit Falls - Update
11/5/2009 8:37 AM ET

RELATED NEWS
King Pharma Appoints Kevin Crutchfield And Derace Lan Schaffer To Board - Quick Facts
King Pharmaceuticals To Present At J.P. Morgan Healthcare Conference; Webcast At 5:30 PM ET
King Pharmaceuticals To Present At J.P. Morgan Healthcare Conference; Webcast At 5:30 PM ET
King Pharmaceuticals Finished At New High For Year Thursday
King Pharmaceuticals To Present At Credit Suisse Healthcare Conference; Webcast At 11:00 AM ET

Trade KG now with
(RTTNews) - Drug maker King Pharmaceuticals Inc. (KG: News ) posted third-quarter profit that nearly halved from last year, reflecting higher costs and expenses. However, quarterly revenues advanced 19% on branded pharmaceutical and Animal Health sales, as well as an increase in sales of Auto-Injectors in the Meridian business.

Q3 Results

The Bristol, Tennessee-based company's third-quarter net income was $42.5 million or $0.17 per share, compared to $82.5 million or $0.34 per share in the prior-year quarter.

On a non-GAAP basis, net income, excluding certain special items and recurring non-GAAP adjustments, dropped to $71.3 million or $0.29 per share from $95.4 million or $0.39 per share last year.

On average, 15 analysts polled by Thomson Reuters expected the company to post earnings of $0.27 per share. Analysts' estimates typically exclude special items.

Total revenues for the quarter were $463.3 million, up 19% from the previous year's revenue of $388.4 million. Fourteen Wall Street analysts had a consensus revenue estimate of $444.98 million for the quarter.

Quarterly revenue growth of 19% was attributed primarily to branded pharmaceutical and Animal Health sales recorded as a result of the Alpharma acquisition and an increase in sales of Auto-Injectors in the Meridian business.

Brian Markison, Chairman, President and Chief Executive Officer of King Pharma, said, "The transformation of King to a fully integrated specialty pharmaceutical company was further supported by strong third quarter performances reported by each of our business segments."
The company added that the third-quarter results reflect strong cash flow from operations as well as a significant repayment of debt associated with the Alpharma acquisition, including complete repayment of the $200 million term loan in October.

Corporate Items

During the quarter, total cost of revenues grew to $162.8 million from $101.5 million last year, and total selling, general, and administrative expense amounted to $135.7 million, up from the prior-year's $99.3 million. Total operating costs and expenses rose to $376.2 million from $265.6 million in the year-earlier quarter.

Operating income for the recent quarter declined to $87.2 million from $122.8 million reported a year ago. Non-GAAP operating income was $129.4 million for the third-quarter of 2009, compared to $138.1 million earned in the prior-year period.

Business Segments

The company's branded pharmaceuticals generated third-quarter net revenues of $283 million, down from $302 million in the third quarter of 2008, primarily due to the sales declines of its THROMBIN-JMI product and the market entry of generic substitutes for ALTACE beginning in December 2007, offset by the addition of revenues from sales of FLECTOR PATCH and EMBEDA.

To receive FREE breaking news email alerts for King Pharmaceuticals, Inc and others in your portfolio


 1   2   Next Page 


Share Article:   Del.icio.us    Digg    Y! My Web    Facebook    My Space

Email        Print           Follow Us RTTNews on Facebook RTTNews on MySpace RTTNews on YouTube

     
Top Stories
Micron Technology Agrees To Buy Privately-held Numonyx For US$1.27 Bln Stock - Update

EOG Resources Q4 Profit Down 13%; Raises Quarterly Dividend - Update

UDR Q4 FFO Declines; Guides FY10

Baidu Q4 Profit Up 48.2%; Guides Q1 Revenue Above Estimates

IMS Health Profit Declines 27%

Earnings
EOG Resources Q4 Profit Down 13%; Raises Quarterly Dividend - Update

Taiga Building Products Swings To Profit In Q3 - Quick Facts

BHP Billiton Half-year Attributable Profit Jumps; Revenue Declines 17.5%; Economic Outlook Cautious - Quick Facts

Ridley Q2 Profit Rises - Quick Facts

Emcore Q1 Loss Narrows; Guides Q2 Revenues - Quick Facts

US Market Commentary
Stocks Post Strong Gains Amid Prospective Greece Bailout - U.S. Commentary

Stocks Hovering Near Highs In Mid-Afternoon Trading - U.S. Commentary

TSX Jumps On Greece Rescue Rumors

Stocks Building On Strong Gains In Early Afternoon Trading - U.S. Commentary

Stocks Give Back Ground But Remain Mostly Higher - U.S. Commentary

US Economic News
ABC News Consumer Confidence Improves Slightly

Reports: Germany Yet To Decide On Possible Aid Package To Greece

Bernanke Hearing Postponed Due To Weather

Wholesale Inventories Show Unexpected Decrease In December

Wholesale Inventories Fell 0.8% In December

Political News
Nigerian Vice-President Goodluck Jonathan Assumes Presidential Powers

Obama: International Community Moving Quickly Towards Iran Sanctions

Obama Calls For Give And Take With GOP

EU Parliament Approves New European Commission

Rubio Endorsed By Conservative Leader In Florida Senate Primary




 
President Urges Congressional Leaders To Negotiate
02/09/10 05:23
Wall Street Bounces Back Tuesday
02/09/10 05:11
Stocks Sharply Higher In Mid-Day Trading
02/09/10 02:44
 

Today's Stocks to Watch
PSOF - Pansoft Company Limited
RBCN - RUBICON TECHNOLOGY,
NTUR.OB - Natural Blue Resources, Inc.
SNSS - Sunesis Pharmaceuticals Inc.
SITO.OB - Single Touch Systems Inc.
MKTX - MARKETAXESS HOLDINGS INC


Hopes of Diffusion of European Debt Crisis May Lead to Some Bargain Hunting
The major U.S. index futures are pointing to a higher opening on Tuesday, with European debt concerns receding following indications from European Commission officials that they may step in to save Greece from getting mired in the debt crisis. Commodity prices are extending their gains and this coupled with the oversold levels of the markets may support a bounce back. Given the fact that the wholesale inventories report to be released after the markets close is not market moving, the markets may derive support from hopes that the economic revival may not lose steam despite the surrounding uncertainty.
The Week In Washington  Lawmakers spent a busy week in Washington discussing the recently unveiled Fiscal Year 2011 budget, and the Democrats new jobs agenda

 

Copyright © 2010 RTTNews. All rights reserved. By using this site, you agree to the Terms of Service.

Feedback| Terms of Service| How To Use RTTNews.com| Advertise| Privacy| Buy Content | RSS